Search

Displaying results 8531 - 8540 of 10000 in total
  1. Drug

    SLV319

    go.drugbank.com/drugs/DB05077
    Experimental

    SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor.

    Categories: Heterocyclic Compounds, 1-Ring
  2. Drug

    HY10275

    go.drugbank.com/drugs/DB05079
    Experimental

    HY10275 is a novel compound specifically designed to modulate two key neurobiological mechanisms that interfere with the sleeping process.

  3. Drug

    VPM4001

    go.drugbank.com/drugs/DB05089
    Experimental

    Interferon-γ enhances presentation of tumour antigens, whereas interleukin-2 stimulates T cells. … It consists of irradiated human LNCaP cells that have been genetically modified to permanently secrete interferon-γ and interleukin-2 (LNCaP/IL-2/IFN-γ).

  4. Drug

    FP0011

    go.drugbank.com/drugs/DB05090
    Experimental

    FP0011 is a small molecule antiglutamatergic compound with symptomatic and disease modifying effects in a variety of neurological disorders (amyotrophic lateral sclerosis and Parkinson's disease).

  5. Drug

    Matuzumab

    go.drugbank.com/drugs/DB05101
    Investigational

    Matuzumab (formerly known as the experimental drug, EMD 72000) is a humanized monoclonal antibody used in cancer treatment. … It has a high affinity for EGFR (epithelial growth factor receptor), frequently associated with the growth of blood vessels in malignancy, facilitating tumor growth and survival.

  6. Drug

    Pleconaril

    go.drugbank.com/drugs/DB05105
    Investigational

    Pleconaril is an antiviral drug from viral capsid inhibitor class, manufactured by Schering-Plough and intended for the prevention of acute asthma exacerbations and common cold symptoms in asthmatic patients who have had exposure to pico...

    Categories: Heterocyclic Compounds, 1-Ring
  7. Drug

    EHT899

    go.drugbank.com/drugs/DB05108
    Experimental

    EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. … It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.

  8. Drug

    AP5280

    go.drugbank.com/drugs/DB05112
    Experimental

    AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.

  9. Drug

    NN344

    go.drugbank.com/drugs/DB05115
    Experimental

    NN344 is a neutral, soluble long-acting human insulin analogue with 24 hour coverage by once daily injection. NN344 has a very flat and predictable action profile.

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme Inducers
  10. Drug

    RAV12

    go.drugbank.com/drugs/DB05140
    Investigational

    RAV12 is a solid. RAV12 is a chimeric antibody that recognizes RAAG12, an N-linked carbohydrate antigen found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells.